Fresh analysis suggests that individuals who discontinue popular slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle plans.
Research printed in a major medical journal points out that while obese people can lose substantial amounts of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such medications should be informed of the risk of fast rebound weight gain when the treatment ends," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original weight in about one and a half years.
Comparing Treatments
The research, which reviewed dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.
The team note that people who shed pounds through diet and exercise usually have a less rapid creep back—around 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Doctors suggest the mode of action of the injections explains the accelerated regain.
These medications imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
The NHS suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, due to the high risk of weight regain, the treatment is often life-long.
This opinion is echoed by drug manufacturers, who say that the findings "highlight the persistent nature of excess weight," similar to managing conditions like hypertension.
Patient Testimonies
Users who have stopped the medication explain a intense resurgence of cravings.
"It felt as if a trigger activating and you're instantly ravenous," described a patient.
The struggle is exacerbated if users have not established permanent lifestyle or habit modifications during treatment.
Growing Use
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Adoption is more common among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic cure and lasting health benefits hinges on ongoing lifestyle management.
